LITERATURE REVIEW: PARKINSON’S DISEASE
DOI:
https://doi.org/10.55640/Keywords:
Parkinson’s disease; neurodegeneration; α-synuclein; Lewy bodies; dopaminergic neurons; basal ganglia; motor symptoms; non-motor symptoms; deep brain stimulation; neuroprotection.Abstract
Parkinson’s disease is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra and the accumulation of α-synuclein aggregates known as Lewy bodies. Clinically, the disease presents with cardinal motor symptoms such as resting tremor, bradykinesia, and rigidity, while a wide range of non-motor manifestations—including cognitive impairment, autonomic dysfunction, sleep disturbances, and mood disorders—often precede motor onset. Modern therapeutic strategies are primarily symptomatic and aim to restore dopaminergic transmission through pharmacological treatments or deep brain stimulation. Despite significant advances, no current therapy effectively halts or reverses neurodegeneration. Ongoing research focuses on biomarkers, genetic mechanisms, immunotherapies targeting α-synuclein, and neuroprotective approaches to modify disease progression.
Downloads
References
1.Bloem, B. R., Okun, M. S., & Klein, C. (2021). Parkinson’s disease. The Lancet, 397(10291), 2284–2303.
2.Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., ... & Lang, A. E. (2017). Parkinson disease. Nature Reviews Disease Primers, 3, 17013.
3.Kalia, L. V., & Lang, A. E. (2015). Parkinson’s disease. The Lancet, 386(9996), 896–912.
4.Braak, H., Del Tredici, K., Rüb, U., de Vos, R. A., Jansen Steur, E. N., & Braak, E. (2003). Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiology of Aging, 24(2), 197–211.
5.Schapira, A. H. V., Chaudhuri, K. R., & Jenner, P. (2017). Non-motor features of Parkinson disease. Nature Reviews Neuroscience, 18, 435–450.
6.Travagli, R. A., & Ferrarese, C. (2022). Pathophysiology of Parkinson’s disease. Cellular and Molecular Neurobiology, 42(4), 775–797.
7.Obeso, J. A., Stamelou, M., Goetz, C. G., Poewe, W., Lang, A. E., Weintraub, D., ... & Schapira, A. H. (2017). Past, present, and future of Parkinson’s disease: A special essay on the 200th Anniversary of the Shaking Palsy.
Movement Disorders, 32(9)
8.Deuschl, G., Schade-Brittinger, C., Krack, P., et al. (2006).
A randomized trial of deep-brain stimulation for Parkinson’s disease. New England Journal of Medicine, 355(9), 896–908.
9.Armstrong, M. J., & Okun, M. S. (2020).
Diagnosis and treatment of Parkinson disease. JAMA, 323(6), 548–560.
Surmeier, D. J., Obeso, J. A., & Halliday, G. M. (2017).
10. Selective neuronal vulnerability in Parkinson disease. Nature Reviews Neuroscience, 18(2), 101–113.
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.

Germany
United States of America
Italy
United Kingdom
France
Canada
Uzbekistan
Japan
Republic of Korea
Australia
Spain
Switzerland
Sweden
Netherlands
China
India